NDC product
Refenesen Mucus Relief
NDC 10956-845 · Reese Pharmaceutical Co
Key facts
| Product NDC | 10956-845 |
|---|---|
| Proprietary name | Refenesen Mucus Relief |
| Nonproprietary name | Guaifenesin |
| Substances | GUAIFENESIN |
| Dosage form | TABLET |
| Route | ORAL |
| Labeler | Reese Pharmaceutical Co |
| Product type | HUMAN OTC DRUG |
| Marketing category | OTC MONOGRAPH DRUG |
| Application number | M012 |
| Pharmacologic classes | Decreased Respiratory Secretion Viscosity [PE], Expectorant [EPC], Increased Respiratory Secretions [PE] |
| Marketing start | Apr 15, 2021 |
| Listing certified through | Dec 31, 2026 |
At a glance
- 1–9 Package NDCs
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About National Drug Codes (NDC)
The National Drug Code (NDC) is the FDA's product identifier for drugs; the product NDC identifies the labeler and product, and each package adds a package code.
Source: U.S. Food and Drug Administration (FDA), National Drug Code Directory · Source date: